MADISON, Wis.--(BUSINESS WIRE)-- Roche NimbleGen (SWX:RO) (SWX:ROG) (Pink Sheets: RHHBY) today announced that one of New Zealand’s largest medical laboratories has adopted the NimbleGen CGX Cytogenetics Microarray Solution. Canterbury Health Laboratories has implemented the NimbleGen workflow solution for Cytogenetics including arrays, reagents, instruments, and software at their core facility in Christchurch, New Zealand. The laboratory will be initially implementing the NimbleGen CGX-12 arrays for their research on developmental delay and mental retardation. These arrays provide targeted cytogenetic content based on the analysis of over 40,000 research samples and include several multiplex formats that enable accurate, high-resolution analysis of up to 12 samples in parallel.
Canterbury Health Laboratories is the largest tertiary medical testing laboratory in New Zealand performing its services for all of New Zealand as well as other Asia Pacific regions including Australia. The laboratory has the most extensive medical research experience in New Zealand and has associations back to the first Pathology Department in the country which was established in 1912 in Christchurch. Since then, it has developed into a leader in New Zealand for medical and genetic research including neonatal cytogenetic testing. For more information, please visit: www.cdhb.govt.nz/chlabs
“At Canterbury Health Laboratories, our mission is to remain as the leading organization for genetic research in New Zealand,” said Professor Peter George, Clinical Director of Canterbury Health Laboratories. “The CGX Cytogenetics Solution from Roche NimbleGen gives us this advanced solution to remain at the forefront with proven cytogenetic content and a tried and tested workflow solution that includes a powerful database of over 10,000 identified genetic alterations that allows us to quickly and easily make sense of our data.”
“We are pleased to partner with leading research laboratories worldwide, such as Canterbury Health Laboratories, who are driven to use advanced technologies to further the understanding of genetic disease,” stated Dr. Frank Pitzer, CEO of Roche NimbleGen. “Their research will provide us with insights to these diseases that can lead to future diagnostics and therapies for these disorders.”
For more information about Roche NimbleGen, please visit www.nimblegen.com
About Canterbury Health Laboratories
Canterbury Health Laboratories is the largest medical laboratory in the South Island, operating from modern, well equipped facilities opposite Christchurch Hospital. It also staffs and maintains smaller laboratories and collection centres at Ashburton, Burwood, and The Princess Margaret Hospitals.
The laboratories perform all testing under the care of the Canterbury District Health Board. In addition daily requests are received to perform specialist tests and research from laboratories between Auckland in the north and Invercargill in the south. It has the biggest ‘catchment’ area and the largest laboratory in New Zealand. While community laboratories are only contracted to perform about 170 different procedures, the contract awarded to Canterbury Health Laboratories encompasses 1,500 different tests. Every laboratory discipline is represented in Canterbury Health Laboratories and annual testing exceeds 3.5 million analyses.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
For life science research only. Not for use in diagnostic procedures.
NIMBLEGEN is a trademark of Roche.
Other brands or product names are trademarks of their respective holders.
KEYWORDS: United States North America Australia/Oceania New Zealand Wisconsin
INDUSTRY KEYWORDS: Technology Software Health Biotechnology Clinical Trials Genetics Medical Devices Mental Health Pharmaceutical